(thirdQuint)Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF) in Subjects With Clostridium Difficile Infection.

 This study is designed primarily to obtain information on the preliminary efficacy, safety and immunogenicity of ACAM-CDIFF cent vaccine, as compared to placebo in subjects who are experiencing their first event of CDI and are being treated with the antibiotic standard of care.

 This study will be conducted in the United States and United Kingdom.

 Adult subjects with limited chronic disease, who are currently receiving treatment for their first episode of CDI will be enrolled in this trial.

 Subjects will be required to be able to take oral antibiotics.

.

 Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF) in Subjects With Clostridium Difficile Infection@highlight

Primary objective: To compare the event rate of CDI in groups assigned to ACAM-CDIFF cent vaccine versus placebo in the 9 week period after the third dose of the study vaccine in subjects with first episode of CDI receiving antibiotics standard of care.

 Secondary objective: To evaluate the safety of all dose groups of ACAM-CDIFF cent vaccine versus placebo in subjects with first episode of CDI receiving antibiotics standard of care.

